GAS6 and COVID-19: Lastly, it is noteworthy that the continuous biotechnological progresses in the field of COVID-19 biomarkers discovery have also led to new and promising findings in terms of possible therapeutic approaches, as demonstrated by the anti-inflammatory and anti-viral activity of heparin [198,199,200], by the ability of IL6 and other IL- and cytokine-signaling inhibitors to improve the disease course [101,102,109,110,201,202,203,204,205] and by the promising antiviral effects of the already existing Gas6/TAM axis inhibitors [131,150,151].